
Data collection is key in tackling antimicrobial resistance

CHMP recommends five new medicines for approval in the EU

Tool is an example of integrating AI in clinical trials

Seizing opportunities in a changing medicines landscape

Patients invited to report suspicious offers

Patients can now locate and enrol in trials in their area
Find medicine
What's new
FAQs
Latest news

Data comes from EU27 plus Iceland and Norway
Benefits continue to outweigh risks, with new risk minimisation measures and more information to be provided about long-term effect on the heart

Five new medicines recommended for approval; another seven medicines recommended for extension of their therapeutic indications

Manufacturers can request advice on their medical device clinical development programme

Artificial intelligence tool reliably identifies disease severity and reduces variability

Seizing opportunities in a changing medicines landscape
Events
EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...
This meeting brings together the members of the Patients and Consumers Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP).
This meeting brings together the members of the Patients and Consumers Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP).
The 3RsWP is hosting this virtual public session to present the 3RsWP work plan and priorities for 2025-2027